Compare · NVO vs ONC
NVO vs ONC
Side-by-side comparison of Novo Nordisk A/S (NVO) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 4.1x ONC ($42.53B).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for ONC).
- NVO has more recent analyst coverage (25 ratings vs 7 for ONC).
- Company
- Novo Nordisk A/S
- BeOne Medicines Ltd.
- Price
- -
- -
- Market cap
- $173.66B
- $42.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 7
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest ONC
- SEC Form 4 filed by BeOne Medicines Ltd.
- SVP, General Counsel Lee Chan Henry sold $418,125 worth of American Depositary Shares (1,115 units at $375.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Chair, Scientific Advisory Brd Wang Xiaodong exercised 31,028 units of American Depositary Shares at a strike of $36.90 and sold $11,318,558 worth of American Depositary Shares (31,028 units at $364.79) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.
- Chair, Scientific Advisory Brd Wang Xiaodong sold $13,366,092 worth of American Depositary Shares (38,287 units at $349.10) as part of a pre-agreed trading plan and exercised 31,027 units of American Depositary Shares at a strike of $36.90, closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Ball Titus B. sold $46,974 worth of American Depositary Shares (132 units at $355.86), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
- BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
- BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
- President and COO Wu Xiaobin sold $106,400 worth of American Depositary Shares (280 units at $380.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)